Suda K, Tomizawa K, Osada H, et al. Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation [J]. Lung Cancer. 2012 ,76(3):292-299.
[2]
Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins [J]. J Clin Invest,2008,118:2609-2619.
[3]
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial [J]. JAMA,2003 ,290(16):2149-58. PubMed PMID:14570950.
[4]
Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC):new developments and implications for future treatment[J]. Lung Cancer,2012,77(1):2-8.
[5]
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med,2009 ,361(10):947-57. Epub 2009 Aug 19. PubMed PMID: 19692680.
[6]
Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J]. Lancet Oncol, 2010,11:521-529.
[7]
Nurwidya F, Takahashi F, Murakami A, et al. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors [J]. Respir Investig,2014 ,52(2):82-91.
[8]
Hata A, Katakami N, Yoshioka H, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations [J]. Cancer,2013 ,119(24):4325-4332.
[9]
Peled N, Wynes MW, Ikeda N, et al. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer [J]. Cell Oncol (Dordr),2013,36(4):277-288.
[10]
Gelsomino F, Facchinetti F, Haspinger ER, et al. Targeting the MET gene for the treatment of non-small-cell lung cancer [J]. Crit Rev Oncol Hematol,2014,89(2):284-299.
Noro R,Gemma A,Kosaihira S, et al. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation [J].BMC Cancer,2006,6:277.
[14]
Koizumi F, Shimoyama T, Taguchi F, et al. Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib [J]. Int J Cancer, 2005,116(1):36-44.
[15]
Rho JK, Choi YJ,Lee JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line [J].Lung Cancer,2009,63(2):219-226.
